Eurobio Scientific: Résultat du 1er semestre 2026

Eurobio Scientific reported H1 2026 revenue of €84.5M, up 4.5% year on year, EBITDA of €15.8M (+20%), and net income of €4.7M (+96%). Proprietary-product revenue rose 10% to €31.3M and accounted for 37% of sales, while free cash flow before acquisitions was €4.0M. The group completed its CareDx Lab Solutions acquisition on 30 June, financed largely by €154.4M from EB Development, lifting net debt including the shareholder account to €147.4M; EB Development also plans a €25.30-per-share buyout and squeeze-out of remaining minorities. Risks include flat organic revenue and Seegene's planned direct entry into France from January 2027, though contractual arrangements may preserve certain existing business.

Analysis

ALERS is no longer an operating-growth equity in practice; it is an event-driven stub with a defined €25.30 cash-out reference, subject to AMF clearance and the independent expert’s fairness opinion. The relevant return is the annualized spread to the offer price rather than earnings upside. Thin Euronext Growth liquidity and a 90%+ controlling holder make downside liquidity asymmetric if the timetable slips, while a mandatory squeeze-out would cap upside at the offer consideration.

The earnings quality is mixed beneath the improved reported profitability: organic group sales were flat, while legacy distribution exposure is contracting as a major supplier transition approaches. The acquired CareDx lab-assets platform could eventually replace that revenue pool and improve mix, but the financing structure transfers the key issue from operating leverage to related-party creditor leverage. The €164.7m shareholder financing is roughly 5x annualized first-half EBITDA before any acquisition contribution; the acquisition must generate substantial, recurring cash conversion to prevent future capital-allocation constraints after delisting.

For CDNA, the divestiture removes a non-core lab-solutions asset base but creates a cleaner diagnostic-transplantation competitive configuration. Eurobio’s expanded European distribution footprint could pressure CDNA’s remaining international commercialization economics if it retains adjacent transplant products, although the more immediate read-through is neutral until CDNA discloses purchase consideration, stranded costs, transition-service obligations, and any impact on its cash runway. WGS has no direct read-through beyond a modest validation that specialty diagnostics assets can find strategic buyers, not necessarily at public-market multiples.

Contrarian view: the market may focus on the headline earnings improvement, but minority holders have limited participation in any CareDx synergy because the bid predates proof of contribution and is fixed. Conversely, a challenge to the price is not a fundamental long thesis: it is a procedural/timing option whose payoff depends on the expert report and AMF process, with limited upside unless the price is revised.

Key Decisions for Investors

• ALERS: treat solely as merger-arbitrage. Buy only if the discount to €25.30 implies an attractive annualized return after allowing 3-6 months for AMF review and low-liquidity execution; target is €25.30, with exit on adverse expert opinion, AMF delay beyond the modeled timetable, or evidence the offer will not proceed.
• Do not underwrite ALERS on H2 operating momentum. Set an alert for disclosed Lab Solutions revenue, EBITDA contribution, integration costs, and the final terms/rate/maturity of EB Development financing; absent these data, the post-deal fundamental value cannot be reliably assessed.
• CDNA: remain neutral pending the next filing/earnings release. Upgrade only if divestiture proceeds are material relative to cash needs and management quantifies lower operating losses or reduced dilution; short-term risk is that lost revenue or transition costs outweigh any balance-sheet benefit.
• Avoid a directional WGS trade from this transaction. Monitor only as an M&A-comparables datapoint; a broader specialty-diagnostics rerating would require multiple comparable asset sales with disclosed valuations, not a single strategic carve-out.